Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease

Robert P. Nelson Jr., Stephen Jolles, Michael Borte, Mikhail Rojavin, Martin Bexon, John-Philip Lawo, Richard L. Wasserman
  • Clinical Immunology, February 2014, Elsevier
  • DOI: 10.1016/j.clim.2013.10.008
The author haven't finished explaining this publicationThe author haven't finished explaining this publication
Read Publication

http://dx.doi.org/10.1016/j.clim.2013.10.008

The following have contributed to this page: Dr Richard L Wasserman